Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.

Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary, ...

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.

Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and ...

Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by ...

Roche on Wednesday said that third-quarter sales gained a currency-adjusted 9% to 15.14 billion Swiss francs ($17.46 billion) ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

International science and technology firm Merck has announced investment of over £4 million in its Life Science facility in Livingston, bringing new jobs to the town. The investment in ...